Viatris And Biocon Launch Bevacizumab Biosimilar In Canada

Abevmy Version Of Avastin Faces Multiple Other Biosimilar Rivals In The Market

Viatris and Biocon have introduced their Abevmy biosimilar bevacizumab version of Avastin in Canada. Marking the third oncology biosimilar – and the fourth biosimilar overall – to be launched by Viatris in Canada, the product will face multiple other approved bevacizumab rivals in the market.

Canada flag five vials syringes
Abevmy is the fifth Avastin biosimilar approved in Canada • Source: Shutterstock

Viatris and Biocon have launched their Abevmy (bevacizumab) biosimilar rival to Avastin in Canada, representing the third oncology biosimilar – and the fourth biosimilar overall – to be launched by Viatris in the market. The product is available in 100mg/4ml and 400mg/16ml single-use vials.

Ogivri (trastuzumab), Canada’s first Herceptin biosimilar to be approved, was launched in 2019, while Fulphila (pegfilgrastim) followed in 2020. Then...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.